沙库巴曲缬沙坦钠片联合叶酸治疗对H型高血压患者血压、sdLDL-C水平及血浆Hcy的影响

Effects of Shakubactril valsartan sodium tablets combined with folic acid on blood pressure,sdLDL⁃C levels,and plasma Hcy in patients with H⁃type hypertension

目的 探讨沙库巴曲缬沙坦钠片联合叶酸治疗对H型高血压患者血压、sdLDL-C水平及血浆Hcy的影响。方法 选取2021年10月至2022年9月于淄博市第一医院进行治疗的176例H型高血压患者为受试者,按照随机双盲法将其分为2组。对照组受试者采用沙库巴曲缬沙坦钠片进行治疗;研究组受试者在对照组基础上给予叶酸进行治疗。观察两组受试者临床疗效、血压、血脂代谢指标、血清炎症指标情况。结果 研究组受试者临床疗效总有效率为92.05%远高于对照组,差异有统计学意义(χ^(2)=3.965,P<0.05)。研究组受试者治疗后收缩压,舒张压均低于对照组,差异有统计学意义(t=6.007、4.186,P<0.05);经治疗后,研究组受试者血脂代谢指标TC、TG、HDL-C、LDL-C和sdLDL-C水平均较对照组低,差异有统计学意义,(t=19.705、19.105、13.304、13.466、10.713,P<0.05);两组受试者经治疗后,研究组受试者血清炎症指标IL-6、TNF-α、hs-CRP、Hcy均优于对照组,差异有统计学意义(t=19.705、19.105、13.304、13.466、10.713,P<0.05)。结论 沙库巴曲缬沙坦钠片联合叶酸治疗H型高血压具有较好的临床效果,能有效降低H型高血压患者的血压,改善患者血脂情况,同时降低患者体内的血清炎症指标,具有较高的临床应用价值,值得推广。

Objective To explore the effect of captopril,valsartan and folic acid treatment on blood pressure,SDLDL-C(Small dense low-density lipoprotein cholesterol)levels and plasma Hcy(Plasma homocysteine)in patients with H-type hypertension.Methods A total of 176 patients with H-type hyperten-sion who were treated at the hospital from October 2021 to September 2022 were selected as subjects.They were divided into two groups using a randomized double-blind method.The control group received treatment with savo and valtracortin sodium tablets.While the the research group received treatment with folic acid in ad-dition to the control group.Results The overall clinical efficacy rate of the subjects in the research group was 92.05%,which was significantly higher than that in the control group(χ^(2)=3.965,P<0.05).The systolic and di-astolic blood pressure of the subjects in the study group were lower than those in the control group after treat-ment,and the difference was statistically significant(t=6.007,4.186,P<0.05).After treatment,the levels of TC,TG,HDL-C,LDL-C,and sdLDL-C in the study group were lower than those in the control group,and the difference was statistically significant(t=19.705,19.105,13.304,13.466,10.713,P<0.05).After treat-ment,the serum inflammatory markers IL-6 and TNF-α,as well as both hs-CRP and Hcy were superior to those in the control group,and the difference was statistically significant(t=19.705,19.105,13.304,13.466,10.713,P<0.05).Conclusion Shakubatroxobin sodium tablets combined with folic acid have shown positive clinical effects in treating H-type hypertension.This treatment effectively reduces blood pressure,improves the blood lipid levels,and reduces the serum inflammatory markers in patients,due to its high clinical value.It is worth promoting this treatment widely.